91 related articles for article (PubMed ID: 24052625)
1. Metastatic castration-resistant prostate cancer hungers for leucine.
Tee AR
J Natl Cancer Inst; 2013 Oct; 105(19):1427-8. PubMed ID: 24052625
[No Abstract] [Full Text] [Related]
2. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.
Wang Q; Tiffen J; Bailey CG; Lehman ML; Ritchie W; Fazli L; Metierre C; Feng YJ; Li E; Gleave M; Buchanan G; Nelson CC; Rasko JE; Holst J
J Natl Cancer Inst; 2013 Oct; 105(19):1463-73. PubMed ID: 24052624
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression.
Wang Q; Bailey CG; Ng C; Tiffen J; Thoeng A; Minhas V; Lehman ML; Hendy SC; Buchanan G; Nelson CC; Rasko JE; Holst J
Cancer Res; 2011 Dec; 71(24):7525-36. PubMed ID: 22007000
[TBL] [Abstract][Full Text] [Related]
4. Monoterpene glycoside ESK246 from Pittosporum targets LAT3 amino acid transport and prostate cancer cell growth.
Wang Q; Grkovic T; Font J; Bonham S; Pouwer RH; Bailey CG; Moran AM; Ryan RM; Rasko JE; Jormakka M; Quinn RJ; Holst J
ACS Chem Biol; 2014 Jun; 9(6):1369-76. PubMed ID: 24762008
[TBL] [Abstract][Full Text] [Related]
5. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
6. New findings for hormone-resistant prostate cancer.
Kerr C
Lancet Oncol; 2006 Apr; 7(4):292. PubMed ID: 16598888
[No Abstract] [Full Text] [Related]
7. Androgen deprivation before prostate radiotherapy: how long is long enough?
Parker C
Lancet Oncol; 2011 May; 12(5):411-2. PubMed ID: 21440506
[No Abstract] [Full Text] [Related]
8. Novel lipid mediators contributing to androgen receptor therapy resistance in prostate cancer.
Chinni SR
EBioMedicine; 2021 Dec; 74():103696. PubMed ID: 34775352
[No Abstract] [Full Text] [Related]
9. Novel drugs targeting the androgen receptor pathway in prostate cancer.
Mateo J; Smith A; Ong M; de Bono JS
Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
[TBL] [Abstract][Full Text] [Related]
10. Managing prostate cancer: the role of hormone therapy.
Ramirez ML; Keane TE; Evans CP
Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
[TBL] [Abstract][Full Text] [Related]
11. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
12. Regulation of androgen receptor signaling in prostate cancer.
Dehm SM; Tindall DJ
Expert Rev Anticancer Ther; 2005 Feb; 5(1):63-74. PubMed ID: 15757439
[TBL] [Abstract][Full Text] [Related]
13. New indication sought for bicalutamide.
Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
[No Abstract] [Full Text] [Related]
14. Statin derivatives as therapeutic agents for castration-resistant prostate cancer.
Ingersoll MA; Miller DR; Martinez O; Wakefield CB; Hsieh KC; Simha MV; Kao CL; Chen HT; Batra SK; Lin MF
Cancer Lett; 2016 Dec; 383(1):94-105. PubMed ID: 27687622
[TBL] [Abstract][Full Text] [Related]
15. Life after failure of traditional androgen deprivation therapy.
Schellhammer P
Urol Oncol; 2012; 30(4 Suppl):S10-4. PubMed ID: 22795075
[TBL] [Abstract][Full Text] [Related]
16. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
Bryce A; Ryan CJ
Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
Lam ET; Glodé LM
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
[TBL] [Abstract][Full Text] [Related]
18. Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters.
Otsuki H; Kimura T; Yamaga T; Kosaka T; Suehiro JI; Sakurai H
Prostate; 2017 Feb; 77(2):222-233. PubMed ID: 27696482
[TBL] [Abstract][Full Text] [Related]
19. Overcoming castration resistance in prostate cancer.
Tsao CK; Small AC; Galsky MD; Oh WK
Curr Opin Urol; 2012 May; 22(3):167-74. PubMed ID: 22472508
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
